Buchumschlag

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Mike Wenzel, Benedikt Hoeh, Fabienne Hurst, Florestan Koll, Cristina Cano Garcia, Clara Humke, Thomas Steuber, Derya Tilki, Miriam Traumann, Severine Banek, Felix K. H. Chun, Philipp Mandel
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	The Prostate
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer
von: Mike Wenzel, et al.
Veröffentlicht: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
von: Chris H.‐M. Wong, et al.
Veröffentlicht: (2024)

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
von: Michal Jirásko, et al.
Veröffentlicht: (2024)

Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions
von: Yitong Weng, et al.
Veröffentlicht: (2025)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
von: Eli Marie Grindedal, et al.
Veröffentlicht: (2024)

Altered Glycosylation of PSA in Prostate Cancer Tissue
von: Hannu Koistinen, et al.
Veröffentlicht: (2025)

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
von: Irena Abramovic, et al.
Veröffentlicht: (2024)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
von: Anwar E. Ahmed, et al.
Veröffentlicht: (2025)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
von: Shintaro Narita, et al.
Veröffentlicht: (2024)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
von: Penglu Yang, et al.
Veröffentlicht: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2025)

PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions
von: Ali Ayranci, et al.
Veröffentlicht: (2024)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
von: Nicholas Fedele, et al.
Veröffentlicht: (2025)

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
von: Takafumi Yanagisawa, et al.
Veröffentlicht: (2024)

A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening
von: Jian Gu, et al.
Veröffentlicht: (2024)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
von: Mark Kidd, et al.
Veröffentlicht: (2025)

Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors
von: Juliana Arenas Hoyos, et al.
Veröffentlicht: (2024)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
von: Liza M. Kurucz, et al.
Veröffentlicht: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
von: Takeshi Tsutsumi, et al.
Veröffentlicht: (2026)

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
von: Hikari Miura, et al.
Veröffentlicht: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
von: Takanori Tokunaga, et al.
Veröffentlicht: (2025)

Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
von: Andrea Romei, et al.
Veröffentlicht: (2025)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
von: Thomas Büttner, et al.
Veröffentlicht: (2024)

PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
von: Philip Sutera, et al.
Veröffentlicht: (2024)

Cáncer de Próstata. ¿Qué es el antígeno prostático específico?. (La biología del PSA)
von: Juan Fernando Uribe Arcila
Veröffentlicht: (2007)

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer
von: Hemal Semwal, et al.
Veröffentlicht: (2024)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
von: Umang Swami, et al.
Veröffentlicht: (2024)

Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
von: Fabio Matrone, et al.
Veröffentlicht: (2024)

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer
von: Kate L. Mahon, et al.
Veröffentlicht: (2024)

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients
von: Tokiyoshi Tanegashima, et al.
Veröffentlicht: (2024)

Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
von: Baris Esen, et al.
Veröffentlicht: (2025)

A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer
von: Daniel Boiarsky, et al.
Veröffentlicht: (2024)

Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”
von: Tokiyoshi Tanegashima, et al.
Veröffentlicht: (2024)

A single‐center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones
von: Gabriela N. C. De Jesus, et al.
Veröffentlicht: (2024)

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post‐radiotherapy, and those with de novo metastatic disease
von: Philip Vincent Charlton, et al.
Veröffentlicht: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
von: Eric V. Li, et al.
Veröffentlicht: (2024)

A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin‐induced apoptosis in castration‐resistant prostate cancer
von: Pei‐Chen Ye, et al.
Veröffentlicht: (2024)

Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer
von: Zain Abedali, et al.
Veröffentlicht: (2024)

Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer
von: Shingo Ashida, et al.
Veröffentlicht: (2024)